Last reviewed · How we verify

NCT04335747

COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

Terminated Last updated 21 July 2021
What this trial tests

trial testing COVID-19 infection in Rheumatoid Arthritis in 53 participants. Terminated before completion.

Timeline
23 April 2020
Primary endpoint
1 July 2021
1 July 2021

Quick facts

Lead sponsorSalome Kristensen
StatusTerminated
Study typeOBSERVATIONAL
Enrollment53
Start date23 April 2020
Primary completion1 July 2021
Estimated completion1 July 2021
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Salome Kristensen

Who can join

18 and older, any sex, with Rheumatoid Arthritis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of COVID-19 infection

Trials testing the same drug.

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

Other Salome Kristensen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04335747.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing